

We Claim:

1. A compound which is an olanzapine pamoate salt or a solvates thereof.

5

2. A compound as claimed in **Claim 1** wherein the pamoate salt is olanzapine pamoate dimethanolate having a typical x-ray powder diffraction pattern as represented by the following interplanar spacing:

<u>d-spacing</u>	<u>Intensity</u>
11.17	73
9.37	17
8.73	40
8.29	23
7.77	14
7.22	24
6.84	31
6.66	54
6.42	11
6.40	11
6.17	26
5.87	12
5.56	100
4.84	11
4.66	17
4.57	26
4.48	22
4.35	19
4.28	19
4.12	94
4.03	91
3.89	52
3.62	44
3.54	11
3.29	16
3.13	16

To 590

3. A compound as claimed in **Claim 1** wherein the pamoate salt is olanzapine pamoate monohydrate having a

BL
8-10-00 10

typical x-ray powder diffraction pattern as represented by the following interplanar spacing:

<u>d-spacing</u>	<u>Intensity</u>
10.76	98
9.20	62
8.38	85
8.18	24
7.62	20
6.67	18
6.56	18
6.51	20
6.44	20
6.11	26
5.88	22
5.64	15
5.38	100
4.90	11
4.72	12
4.64	17
4.48	18
4.35	23
4.29	31
4.24	32
4.09	71
4.02	84
3.98	73
3.81	23
3.62	14
3.52	30
3.39	11
3.25	12
2.90	15
2.85	13

4. A compound as claimed in **Claim 1** wherein the

5 pamoate salt is bis(olanzapine) pamoate acetone solvate having a typical x-ray powder diffraction pattern as represented by the following interplanar spacing:

<u>d-spacing</u>	<u>Intensity</u>
16.87	32
9.58	35
8.88	80
8.40	16
8.19	35

To 601

60

7.85	16
7.34	29
7.22	25
7.04	30
6.87	18
6.77	11
6.73	11
6.65	21
6.36	12
6.26	26
5.76	31
5.58	79
5.53	100
5.45	61
5.32	42
5.19	39
5.02	55
4.91	69
4.87	51
4.85	57
4.69	44
4.61	68
4.44	23
4.34	14
4.18	17
4.07	36
3.99	28
3.93	65
3.81	23
3.78	24
3.77	20
3.65	23
3.59	28
3.45	13
3.32	19
3.25	26

5. A compound as claimed in **Claim 1** wherein the pamoate salt is bis(olanzapine) pamoate monohydrate solvate having a typical x-ray powder diffraction pattern as represented by the following interplanar spacing:

5 represented by the following interplanar spacing:

<u>d-spacing</u>	<u>Intensity</u>
15.77	26
10.44	23
9.64	24
9.31	13

8.27	23
8.17	14
8.13	14
7.84	27
7.81	30
7.41	60
7.12	40
7.00	13
6.96	13
6.55	45
6.18	53
5.87	38
5.80	19
5.59	89
5.25	26
5.00	34
4.96	31
4.88	61
4.85	73
4.71	34
4.52	19
4.33	11
4.19	100
4.12	48
4.05	39
3.97	30
3.89	31
3.80	29
3.72	20
3.70	21
3.58	33
3.45	27
3.04	13
2.84	16

—

6. A compound as claimed in **Claim 1** wherein the pamoate salt is olanzapine pamoate THF solvate having a typical x-ray powder diffraction pattern as represented by
 5 the following interplanar spacing:

<i>Td620</i>	<u>d-spacing</u>	<u>Intensity</u>
	14.59	100
	7.78	16
	7.24	56
	7.00	19

6.37 12
6.04 11
6.01 11
4.85 19
4.69 42
4.39 25
4.28 19
3.95 13
3.84 20

7. A method of treating an animal, including a
human suffering from or susceptible to psychosis, acute
mania or mild anxiety states which comprises administering a
5 pharmaceutically effective amount of a compound of **Claim 1,**
2, 3, 4, 5 or 6.